Pharma Focus Europe

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries

Tuesday, January 24, 2023

IntelGenx Corp., a leader in pharmaceutical films, announced today that it has entered into an exclusive supply agreement for RIZAPORT® (the “Product”) with ARWAN Pharmaceuticals Industries Lebanon s.a.l. (“ARWAN”) in various countries in the Middle East and North Africa (“MENA”) region, including Lebanon, Kuwait, Saudi Arabia, United Arab Emirates, Jordan, Iraq, , Libya, Oman, Yemen, Qatar, Bahrain, Egypt, Sudan, Kenya, Nigeria, Mauritius, Cameroon, Afghanistan, Tajikistan, Kazakhstan, Turkmenistan, and Uzbekistan (the “Territory”).

RIZAPORT® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt®. Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms.1 RIZAPORT® is based on IntelGenx's proprietary VersaFilm® technology. It dissolves rapidly and releases its active ingredient in the mouth. The administration method of the RIZAPORT® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a therapeutic alternative for migraine patients, especially for those who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population, and for patients suffering from dysphagia (difficulty swallowing).1

Under the terms of the Agreement, IntelGenx will supply the Product to ARWAN, which will have the exclusive right to register and commercialize it in the Territory.

“The marketing and distribution of an innovative product like RIZAPORT® requires deep insight into both the treatment and regulatory landscape within a target country,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “ARWAN knows the MENA marketplace intimately, and has a successful track record. We are looking forward to working with them."

"We are excited to bring this innovative and easy-to-administer treatment to patients in the MENA region, where migraine prevalence is similar to that in the rest of the world,” said Abdul Razzaq Yousef, President of ARWAN.

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024